Date: 2014-06-20
Type of information: Preclinical data
phase: preclinical
Announcement: preclinical results
Company: Kadimastem (Israel)
Product:
Action mechanism:
Disease: amyotrophic lateral sclerosis
Therapeutic area: Neurodegenerative diseases - Rare diseases
Country:
Trial details:
Latest
news: * On June 20, 2014, Kadimastem reported results of a preclinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The trial examined the effectiveness of injecting Kadimastem’s support cells (astrocytes) into the spinal fluid of a mouse model of ALS. The results of the trial showed an increased life expectancy for the mice injected with the cells. In addition, there was a significant improvement in the motor (muscle) function of the treated mice compared to those that were untreated. The effectiveness of the treatment is also reflected in other indices indicating a delay in disease onset. Injections into spinal fluid are a standard procedure done routinely in hospitals around the world. Kadimastem found that such injections enable the cells to disperse throughout the central nervous system, and it thus established the method of cell penetration in future treatment of patients. In light of the positive results of the preclinical trial, Kadimastem intends to conduct preliminary talks (pre-IND) with regulatory authorities such as the FDA to pave the regulatory path to conducting clinical trials.
